Zobrazeno 1 - 10
of 1 415
pro vyhledávání: '"Jianying, Zhou"'
Autor:
Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Jie Weng, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Hongying Wei, Jiawei Wei, Zheyu Zhang, Qiong Wu
Publikováno v:
Cancer Communications, Vol 44, Iss 9, Pp 1005-1017 (2024)
Abstract Background The initial randomized, double‐blinded, actively controlled, phase III ANEAS study (NCT03849768) demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first‐line therapy in epidermal growth factor re
Externí odkaz:
https://doaj.org/article/2b6ae05d34ee40d883ed46122a1d5428
Autor:
Caicun Zhou, MD, PhD, You Lu, MD, Sang-We Kim, MD, PhD, Thanyanan Reungwetwattana, MD, Jianying Zhou, MD, Yiping Zhang, MD, Jianxing He, MD, PhD, Jin-Ji Yang, MD, Ying Cheng, MD, Se-Hoon Lee, MD, PhD, Jianhua Chang, MD, Jian Fang, MD, Zhe Liu, PhD, Lilian Bu, MSc, Li Qian, MD, Tingting Xu, MD, Venice Archer, MB ChB, MSc, Magalie Hilton, MSc, Mingzhu Zhou, MSc, Li Zhang, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100700- (2024)
Introduction: Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced ALK-positive NSCLC, consi
Externí odkaz:
https://doaj.org/article/0adb5b401a534eba8c323105cdaa5a38
Autor:
Jingjing Qu, Binggen Wu, Lijun Chen, Zuoshi Wen, Liangjie Fang, Jing Zheng, Qian Shen, Jianfu Heng, Jianya Zhou, Jianying Zhou
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)
Abstract Background Mucosal-associated invariant T (MAIT) cells have been reported to regulate tumor immunity. However, the immune characteristics of MAIT cells in non-small cell lung cancer (NSCLC) and their correlation with the treatment efficacy o
Externí odkaz:
https://doaj.org/article/fd94651871714e86ad5c2ee7727bd109
Autor:
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Publikováno v:
Cancer Communications, Vol 44, Iss 4, Pp 455-468 (2024)
Abstract Background The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib‐refractory, anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC).
Externí odkaz:
https://doaj.org/article/dcd1b31af767472781f48f4856ca4755
Autor:
Jingjing Qu, Yuekang Li, Binggen Wu, Qian Shen, Lijun Chen, Wenjia Sun, Bo Wang, Lixiong Ying, Li Wu, Hong Zhou, Jianya Zhou, Jianying Zhou
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
The role of CD161+CD127+CD8+ T cells in non-small cell lung cancer (NSCLC) patients with diabetes remains unexplored. This study determined the prevalence, phenotype, and function of CD8+ T cell subsets in NSCLC with diabetes. We recruited NSCLC pati
Externí odkaz:
https://doaj.org/article/de02811caa2f4908bcd4631e6583885b
Autor:
Wenjia Sun, Fengqi Qiu, Jing Zheng, Liangjie Fang, Jingjing Qu, Shumeng Zhang, Nan Jiang, Jianying Zhou, Xun Zeng, Jianya Zhou
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Immune checkpoint inhibitors have transformed the treatment landscape of non-small cell lung cancer (NSCLC). However, accurately identifying patients who will benefit from immunotherapy remains a challenge. This study aimed to discover poten
Externí odkaz:
https://doaj.org/article/82c84b58a68f4d70a576d70d69db71c5
Publikováno v:
Photonics, Vol 11, Iss 10, p 970 (2024)
Camouflage is a natural or artificial process that prevents an object from being detected, while camouflage breaking is a countering process for the identification of the concealed object. We report that a perfectly camouflaged object can be retrieve
Externí odkaz:
https://doaj.org/article/e3bbfab948a84a3383010351405b9a77
Publikováno v:
PeerJ, Vol 12, p e17030 (2024)
Background Patients with poor prognosis of pulmonary cryptococcosis (PC) are prone to other complications such as meningeal infection, recurrence or even death. Therefore, this study aims to analyze the influencing factors in the poor prognosis of pa
Externí odkaz:
https://doaj.org/article/61eec61bef914d089ab4d0d5770b196e
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Omalizumab is a valuable alternative treatment for allergic bronchopulmonary aspergillosis (ABPA). The effectiveness and safety of this medication have not been confirmed. The main purpose of this study was to evaluate the effecti
Externí odkaz:
https://doaj.org/article/51fbb47cf2d540338b1657f1df6b545a
Autor:
Yunpeng Yang, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shou’an Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Li Zhang, Wenfeng Fang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-8 (2023)
Abstract Anaplastic lymphoma kinase (ALK) rearrangements are present in about 5–6% of non-small cell lung cancer (NSCLC) cases and associated with increased risks of central nervous system (CNS) involvement. Envonalkib, a novel ALK inhibitor, demon
Externí odkaz:
https://doaj.org/article/2147bdf7a75e4cf189fd4a0c98e7ad89